K-Stat-ET Tablet is a combination pharmaceutical formulation containing Tranexamic Acid 500 mg and Ethamsylate 250 mg, indicated for the management and prevention of excessive bleeding. Tranexamic Acid is an antifibrinolytic agent that inhibits the activation of plasminogen to plasmin, thereby stabilizing formed clots and reducing fibrinolysis. Ethamsylate acts by improving capillary endothelial stability and promoting platelet adhesion, which enhances primary hemostasis. The synergistic effect of these two agents makes K-Stat-ET effective in controlling hemorrhagic conditions such as menorrhagia, postoperative bleeding, dental extractions, and bleeding associated with various surgical procedures. It is also utilized in managing bleeding disorders where clot stabilization is essential. The tablet should be administered under medical supervision, with dosage tailored according to the severity of bleeding and patient response. Contraindications include active intravascular clotting, hypersensitivity to components, and caution is advised in patients with thromboembolic disorders or renal impairment. Adverse effects may include gastrointestinal disturbances, hypersensitivity reactions, and rare thrombotic events. K-Stat-ET Tablet offers a reliable therapeutic option for clinicians aiming to achieve effective hemostasis in diverse clinical scenarios.